Kosan, Bristol-Myers deal

Simultaneously, Bristol-Myers received an exclusive, worldwide license to Kosan’s epothilone compounds as a backup deal. If the acquisition does not go through, Kosan would receive

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE